title: Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
authors.forename: Catherine
authors.initials: C
authors.lastname: Oakman
authors.forename: Erica
authors.initials: E
authors.lastname: Moretti
authors.forename: Christos
authors.initials: C
authors.lastname: Sotiriou
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Viale
authors.forename: Angelo
authors.initials: A
authors.lastname: Di Leo
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D005260:Female; D017353:Gene Deletion; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D018943:Anthracyclines; D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human